Ingenex Inc., of Menlo Park, Calif., an operating company of TitanPharmaceuticals Inc., has received notice of allowance for a patentcovering the company's IGX monoclonal antibody for reversingmultidrug resistance.Houston-based Texas Biotechnology Corp.'s subsidiary,ImmunoPharmaceuticals Inc., of San Diego, has received patentnumber 5,331,573 for a novel rational drug design technology.

(c) 1997 American Health Consultants. All rights reserved.